Soblidotin
Also known as: Auristatin PE, Dolastatin 10 analogue, Soblidotin, TZT-1027, TZT‑1027
Source Soblidotin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Soblidotin (also known as auristatin PE, TZT‑1027) is a synthetic peptide derived from the marine natural product dolastatin‑10. It belongs to the auristatin/dolastatin family of microtubule‑destabilising agents and has been evaluated in early‑phase clinical trials as an investigational anticancer drug, administered intravenously. The compound is being explored for its ability to halt tumour cell division and to overcome resistance to conventional chemotherapy.
Mechanism of Action
Soblidotin binds to the β‑tubulin subunit of tubulin dimers, preventing polymerisation of microtubules. This destabilisation disrupts the mitotic spindle, arrests cells at the metaphase‑anaphase transition and triggers apoptotic cell death. By targeting a core component of cell division, it can affect rapidly proliferating cancer cells and may retain activity in tumours that have become resistant to other microtubule‑targeting drugs.
What the Research Shows
Reviews of marine‑derived anticancer agents list soblidotin among a group of dolastatin analogues that entered clinical testing after promising pre‑clinical activity. The 2015 review of microtubule‑targeting agents notes soblidotin alongside cryptophycins and epothilones as having shown antitumour effects and the capacity to overcome multidrug resistance in laboratory models. Earlier surveys (2004‑2008) record its inclusion in trial registries, but the abstracts provide no detailed efficacy or safety outcomes. Consequently, the published literature supports its mechanistic rationale and early‑phase investigation, while substantive clinical data remain limited.
Reported Benefits
Pre‑clinical data suggest soblidotin can induce potent microtubule disruption, leading to cancer cell death, and may retain activity where other agents fail due to resistance. Review articles cite its anti‑angiogenic and anti‑vascular properties, which could complement its cytotoxic effects. As a synthetic analogue, it offers a defined chemical structure amenable to further optimisation.
Limitations of the Evidence
Evidence for soblidotin is confined to reviews and trial listings; no peer‑reviewed trial results are presented in the abstracts. Its clinical development status is investigational, and the lack of published efficacy data makes it impossible to assess therapeutic benefit. Potential class‑related toxicities and the need for intravenous infusion also limit its practicality pending further study.
Safety Considerations
Microtubule‑destabilising agents are commonly associated with neurotoxicity and myelosuppression, and the abstracts caution that earlier microtubule inhibitors suffered from neurological and bone‑marrow toxicity. Although soblidotin‑specific adverse‑event data are not reported, the same safety concerns are plausible and warrant careful monitoring in any clinical setting.
How It Is Administered
Soblidotin has been administered intravenously in investigational settings. Formulations are typically provided as sterile solutions for infusion; no oral or alternative routes are described in the cited literature.
Routes of Administration
Goals & Uses
- Solid tumor oncologyOncologyModerate
- Non-small cell lung cancer treatmentOncologyModerate
- Antitubulin antineoplastic activityOncologyModerate
- ADC payload candidateOncologyLow
- Soft tissue sarcoma treatmentOncologyModerate
Contraindications
- Severe peripheral neuropathyNeurotoxicityHigh
- Severe hepatic impairmentOrganHighLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- hypersensitivity to soblidotin or excipientsAllergyModerate
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- AlopeciaDermatologicCommonHair loss
- ConstipationGastrointestinalUncommonReduced bowel frequency or difficulty passing stool
- Nausea/vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- Other antineoplasticsModerate
- CYP3A4 inhibitors (e.g., ketoconazole)Moderate
- Other myelosuppressive agentsHigh
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveAbsolute
- Patients with pre-existing neuropathyNeurologicRelative
Regulatory Status
- European UnionInvestigationalClinical trial status; not authorized by EMA
- United StatesInvestigationalInvestigational New Drug (IND) application; no FDA approval
- United KingdomInvestigationalUnder clinical investigation; not licensed by MHRA
Never received regulatory approval in any jurisdiction. Phase II clinical development was conducted in Japan (Teikoku Hormone/Dainippon Sumitomo Pharma) and internationally. No active IND or ongoing pivotal trials are known as of the knowledge cutoff.
Evidence & Sources
- Journal ArticleModerateFanale D, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateSingh R, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateRawat DS, et al.2006-01-01T00:00:00.000000Z
- Journal ArticleModerateBayés M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
- Journal ArticleModerateBayes M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
- Journal ArticleModerateLee Y, Phat C, Hong SC2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer is soblidotin intended to treat?
Soblidotin is being studied as a broad‑spectrum anticancer agent. The abstracts do not specify a particular tumour type, reflecting its evaluation in early‑phase trials across multiple solid tumours.
Is soblidotin approved for clinical use?
No. The compound is listed as investigational and has only been examined in clinical trial registries; it has not received regulatory approval for any indication.
How does soblidotin differ from other microtubule drugs?
It is a synthetic analogue of dolastatin‑10 that binds tubulin dimers to destabilise microtubules, whereas some agents stabilise them. Its design aims to improve potency and overcome resistance seen with earlier microtubule inhibitors.
What are the main safety concerns?
Based on its class, potential adverse effects include peripheral neuropathy and suppression of bone‑marrow function. Specific safety data for soblidotin are not provided in the abstracts, so monitoring for these effects is recommended in trials.
How is the drug given to patients?
In investigational studies soblidotin is delivered by intravenous infusion, typically as a sterile solution prepared for infusion in a clinical setting.
What is Soblidotin?
Soblidotin (also known as auristatin PE, TZT‑1027) is a synthetic peptide derived from the marine natural product dolastatin‑10. It belongs to the auristatin/dolastatin family of microtubule‑destabilising agents and has been evaluated in early‑phase clinical trials as an investigational anticancer drug, administered intravenously. The compound is being explored for its ability to halt tumour cell division and to overcome resistance to conventional chemotherapy.
What is Soblidotin used for?
Soblidotin is educationally associated with: Solid tumor oncology, Non-small cell lung cancer treatment, Antitubulin antineoplastic activity, ADC payload candidate, Soft tissue sarcoma treatment. Educational only — not medical advice.
How is Soblidotin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Soblidotin?
Reported adverse effects include: Peripheral neuropathy, Alopecia, Constipation, Nausea/vomiting, Neutropenia, Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Soblidotin?
Recorded contraindications: Severe peripheral neuropathy, Severe hepatic impairment, Pregnancy, hypersensitivity to soblidotin or excipients. Consult a qualified clinician before use.